Healio (5/2, Gramigna) reported, “Clinical data support the effectiveness of ketamine and esketamine for difficult-to-treat depression and major depressive disorder [MDD] with suicidal ideation, according to” a presentation given by Richard C. Shelton, MD, director of the University of Alabama at Birmingham Depression and Suicide Center, at the American Psychiatric Association virtual annual meeting. During the presentation, Dr. Shelton discussed findings from several studies and outlined “limitations and concerns.” (SOURCE: APA Headlines)
- ) strategy and implementation of activities aimed at increased supports for caregivers of persons with mental illness, in addition to the continued work of the Coalition and sustaining the collaboration between aging and behavioral health providers at the local level.
- Studies Support Effectiveness Of Ketamine, Esketamine For Difficult-To-Treat Depression, MDD With Suicidal Ideation, Expert Says
- In Small Study, Investigational Nondopamine Antipsychotic Show Signals It May Improve Psychosis Symptoms In Patients With Parkinson’s Disease
- Benzoate Treatment Appears To Improve Cognitive Function Among Women With Later-Stage Dementia In Small Study
- More Than One In Ten Patients Who Receive An ICD May Also Develop Anxiety Or Depression, Research Suggests